BANGKOK, Thailand – The Ministry of Public Health has successfully concluded talks with two of the world’s largest pharmaceutical companies, MSD and Roche, with Sandoz and a dozen more global drugmakers next in line.
This is a turning point in the country’s economic strategy: moving Thailand beyond contract manufacturing and into co-developing and co-producing high-technology, high-value products.
What’s on the table: Roche has signalled an initial THB15 billion (approximately US$453 million) in pharmaceutical R&D investment in Thailand, according to Government Spokesperson Dr. Ekkapob Pianpises. With other companies still negotiating, total research funding could reach THB100 baht (approximately US$3 billion). Talks also cover building pharmaceutical manufacturing bases on Thai soil.
Lower-priced access to new medicines for hard-to-treat diseases through Thailand’s universal health coverage system
When a country helps develop a drug, it doesn’t just import the result, it gains the science, the jobs, and a seat at the negotiating table on price. For Thai patients, that means earlier access to breakthrough treatments. For Thai scientists, clinical researchers, and manufacturing talent, it means a whole new career pipeline at home. This is part of Thailand’s broader push to become a Medical Investment Hub in Southeast Asia — a real, measurable deliverable that grows the economy while improving quality of life. Thailand isn’t just open for business. It’s open for discovery. (PRD)
